ESMO 2022 journaal | Gynaecologische tumoren

Dr. Ingrid Boere was bij ons in de studio in Parijs en neemt met presentator Inge Diepman het belangrijkste ESMO-nieuws door op het gebied van de gynaecologische tumoren.

Bent u vooral geïnteresseerd in een specifiek onderwerp? Maak dan gebruik van onze hoofdstukindeling. Deze is te herkennen aan de drie streepjes rechtsonder in de videospeler.

De volgende abstracts worden besproken:

Eerstelijns PARP-remming bij ovariumcarcinoom

• Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
• Final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
• Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

PARP-remming in de recidiefsetting

• Overall survival results from ARIEL4: a phase 3 study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
• Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
• Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Immuuntherapie bij ovariumcarcinoom

• Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
• Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial
• Preliminary results of Sintilimab (Sin)+Bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial

Immuuntherapie bij endometriumcarcinoom

• Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

Immuuntherapie bij cervixcarcinoom

• Phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
• Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in CheckMate 358.
• Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (Phase II): Safe and effective in both PD-L1 positive and negative

Bekijk hier het volledige overzicht van onze ESMO 2022 journaals en interviews.

Wij zijn benieuwd wat u van dit programma vindt en stellen het op prijs als u het evaluatieformulier invult. Gemiddeld duurt het 2 minuten om de enquête te vullen.